Professor of Medicine
BIDMC/Harvard Medical School
Boston, MA

C. Michael Gibson, M.S., M.D. is an interventional cardiologist, cardiovascular researcher & educator. He is the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medical School. The institutes have led over 1,250 studies, published 5,500 manuscripts in the peer review literature (including 144 in the New England Journal) and have led 60 FDA submissions from their network of 7,000 sites worldwide. Since 2014 Gibson has consistently been ranked as one of the world’s most highly cited authors in all of science by Thomson Reuters. In 2021, he was named one of the Fifty of the Most Influential Voices in Healthcare by Medika Life. His work has been cited over 165,000 times.

Gibson has led phase 1-4 clinical trials, and cardiology megatrials of over 34,000 patients which eventuate in international approval of drugs like prasugrel, rivaroxaban and betrixaban. For years, Gibson has been chosen as one of Boston’s Top Doctors & U.S. News & World Report also lists Gibson as one of America’s top doctors. Gibson invented measures of coronary blood flow that are widely used today (the TIMI frame count, the TIMI myocardial perfusion grade).

Dr. Gibson did his internship, residency and chief residency at the Brigham and Women’s Hospital and his cardiology fellowship at the Beth Israel Deaconess Medical Center both at Harvard Medical School.

Gibson founded WikiDoc.org and WikiPatient.org, widely viewed open-source textbooks of medicine. He is Editor-In-Chief of >2,200 active contributors who have edited the content of over 100,000 chapters millions of times. Gibson also founded www.clinicaltrialresults.org and has conducted >2,600 TV / video interviews. Gibson has hundreds of thousands of followers on social media where he is a leading influencer.